SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) (“Crinetics”), a pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing of an underwritten public offering of 7,620,000 shares of its common stock at a price to the public of $45.95 per share. All of the shares to be sold in the offering are to be sold by Crinetics. The gross

COPENHAGEN, Denmark, January 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the share buy-back program announced on December 2, 2025 , under which the Company intends to repurchase own shares for up to DKK 500 million during 2026. The first tranche will comprise buy-back of shares for up to DKK 150 million, which will be held as treasury stock for the purpose of adjusting the capital structure. The share buy-back program is initiated pursuant to the authorization

Collaboration with Amgen to advance a cancer target discovered using DISCO’s proprietary surfaceome mapping technology Cologne, Germany, January 7, 2026 – DISCO Pharmaceuticals (“DISCO”), today announced an exclusive license agreement with Amgen to advance novel therapeutic candidates addressing a target that was mapped on the surface of a cancer cell by DISCO’s proprietary platform. Under the terms of the agreement, DISCO will be eligible to receive up to $618 million total potential deal v

Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 2026 4D-150 PRISM wet AMD 2-year Phase 2b data expected mid-2026 4D-150 DME global Phase 3 trial initiation expected Q3 2026; 2-year SPECTRA Phase 1/2 data expected H2 2026 Appointed Glenn Sblendorio to Board of Directors, adding deep commercial and operating experience, including in

The acquisition strengthens UBC’s leadership in evidence generation offerings with globally recognized expertise in HEOR, medical affairs and market access. KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--United BioSource LLC (UBC) today announced it has acquired Evidinno Outcomes Research Inc. (Evidinno), a healthcare research consulting firm headquartered in Vancouver, Canada specializing in real-world evidence (RWE), epidemiology, evidence synthesis, and advanced statistical & economic analysis. UBC p

— Delivers rapid, durable responses in wAIHA, the more common form of this potentially life-threatening disease — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Phase III registration part of the ESLIM-02 clinical trial of sovleplenib, a novel spleen tyrosine kinase (“Syk”) inhibitor, in adult patients with warm antibody autoimmune hemolytic anemia (“wAIHA”) in China ha

EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, today announced the closing of its previously announced registered direct offering, with a single healthcare-focused institutional investor, for the issuance and sale of 4,063,290 shares of the Company’s common stock and 1,000,000 pre-funded warrants.

SAN ANTONIO, TX / ACCESS Newswire / January 7, 2026 / CellRight Technologies, LLC, a specialist in regenerative allografts for patient implants, announces that it has secured private equity funding from Harwood Capital through its parent company, Tissue Regenix Group plc (TRG) to support commercial growth plans for the business. The management team, led by newly appointed CEO and Chairman, Jay LeCoque, remain focused on restoring TRG revenue growth and profitability, and driving sustainable,

LYON, France--(BUSINESS WIRE)-- #Biotechnology --Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial ( NCT06934538 ) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-1010 1 in a first line setting. It will include in vivo analysis of immune and tum

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the company’s global innovative pipeline. Ascentage Pharma will conduct a global Phase I study evaluating APG-3288 in patients with relapsed/refractory B-cell malignancies. ROCKVILLE, Md. and SUZHOU, China, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855),